Author: John M. Wagner, MD, PhD on January 15, 2020
Happy New Year! By now, you have undoubtedly seen the most recent Clinical and Translational Science (CTS) Impact Factor (IF) of 3.989, a more than two-fold increase over the previous year, and a more than four-fold jump over 2 years. As you know, IF assesses a journal’s performance by calculating how often researchers cite journal papers. Thus, it’s considered an approximation of the influence and scientific rigor of the published research. IF is the number of current year citations of articles published in the two previous years, divided by the number of articles published during those two years, providing a 2-year rolling citation average. The current 2018 IF is the first year that ASCPT “owns” the entire metric. Last year, we owned half the 2017 metric, and the IF was 1.954, while two years ago, the old editorial leadership of CTS accounted for the entire 2016 IF of 0.860. So, you can see the new CTS content and editorial strategy – with a goal of becoming the beacon for the field of translational medicine – have been highly effective.
In the spirit of a 2019 review, we wanted to celebrate our most impactful contributions. Looking forward to the 2019 impact factor, the three most highly cited papers* were:
1. “Lessons Learned from Alzheimer Disease: Clinical Trials with Negative Outcomes” by Cummings, published in August 2017 with 25 citations.
2. “Current Status of Companion and Complementary Diagnostics: Strategic Considerations for Development and Launch” by Scheerens et al., published in January 2017 with 20 citations.
3. “Future of Rare Diseases Research 2017-2027: An IRDiRC Perspective” by Austin et al., published in August 2017 with 18 citations.
IF is just one way to measure journal influence. Another important metric of impact is downloads, which also demonstrated strong results in 2019. Downloads measure how often journal readers take the time to download an article. All three of the top downloaded articles are tutorials, which is consistent with the Journal’s intended positive educational impact on the field of translational medicine. CTS downloads have shown impressive growth since we relaunched in 2016. The three most downloaded articles published in 2019** were:
1. “Tutorial on Monoclonal Antibody Pharmacokinetics and Its Considerations in Early Development” by Ovacik and Lin, published June 2018 with 4,480 downloads.
2. “Regulatory Affairs 101: Introduction to Investigational New Drug Applications and Clinical Trial Applications” by Chiodin et al., published March 2019 with 4,191 downloads.
3. “Current Status of Companion and Complementary Diagnostics: Strategic Considerations for Development and Launch” by Scheerens et al., published in January 2017 with 2,128 downloads and also one of the top-three most cited articles as well.
Looking forward to 2020, we’ve added a Mini-Review article type, which is a concise overview of recent advances in the specified subject area, clocking in at 2,000-3,000 words. One area of focus will be mechanisms of action of therapeutics. Look for this new, exciting category in the coming year.
Thanks to the CTS authors and readers, ASCPT membership, and the many folks who make the Journal work – including editors, reviewers, as well as ASCPT and Wiley staff. CTS had another successful, impactful year on the journey to becoming a beacon of translational medicine. The Journal owes its success to each and every one of you.
Do you have the next IF or download winner? Submit to CTS and find out. Are you curious about the top cited and downloaded papers? Read them today and join us in 2020 to help drive our vision for translational medicine with your submissions.
* Preliminary 2019 impact factor “in-window” citations (i.e., those from articles that will count toward the next IF)
** Usage numbers are through November and are downloads for any article published since 2016.
The comment feature is locked by administrator.